MIRAPRIL

This brand name is authorized in Nigeria.

Active ingredients

The drug MIRAPRIL contains one active pharmaceutical ingredient (API):

1	Lisinopril UNII E7199S1YWR - LISINOPRIL
	Lisinopril is a peptidyl dipeptidase inhibitor. It inhibits the angiotensin-converting enzyme (ACE) that catalyses the conversion of angiotensin I to the vasoconstrictor peptide, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. Inhibition of ACE results in decreased concentrations of angiotensin II which results in decreased vasopressor activity and reduced aldosterone secretion.
	Read more about Lisinopril

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
C4-0442	Tablet	MIRAPRIL-10 TABLETS TAB 10 mg 2 X 14	MIRAPRIL-10 TABLETS MIRAPRIL LISINOPRIL (DIHYDRATE) USP EQ. TO LISINOPRIL 10MG POM TABLETS 2 X 14 ANTIHYPERTENSIVE MIRAFLASH NIG LTD. 2-8 SUCCESS ESTATE, OFF BRENTFIELD AVENUE OKE AFA MAGBORO, OGUN STATE STALLION LABORATORIES PVT LTD C-1B, 305/2,3,4&5, G.I.D.C., KERALA (BAVLA) DIST: AHMEDABAD- 382 220, GUJARAT, INDIA GMP- RBC LR- SATIS; FEES- PAID; NP: NA 16/12/2019 R R R C4-0442	30/01/2020
C4-0443	Tablet	MIRAPRIL-5 TABLETS TAB 5 mg 2 X 14	MIRAPRIL-5 TABLETS MIRAPRIL LISINOPRIL (DIHYDRATE) USP EQ. TO LISINOPRIL 5MG POM TABLETS 2 X 14 ANTIHYPERTENSIVE MIRAFLASH NIG LTD. 2-8 SUCCESS ESTATE, OFF BRENTFIELD AVENUE OKE AFA MAGBORO, OGUN STATE STALLION LABORATORIES PVT LTD C-1B, 305/2,3,4&5, G.I.D.C., KERALA (BAVLA) DIST: AHMEDABAD- 382 220, GUJARAT, INDIA GMP- RBC LR- SATIS; FEES- PAID; NP: NA 16/12/2019 R R R C4-0443	30/01/2020

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C09AA03	Lisinopril	C Cardiovascular system → C09 Agents acting on the renin-angiotensin system → C09A ACE inhibitors, plain → C09AA ACE inhibitors, plain
Discover more medicines within C09AA03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
NG	Registered Drug Product Database	C4-0442, C4-0443